Stockreport

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Foghorn Therapeutics Inc.  (FHTX) 
PDF FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective C [Read more]